Form S-8 Corbus Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RBC Capital Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
June 3, 2024 6:36 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $77.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP)
The analyst comments "Updated ASCO data continue to point to competitive efficacy for their Nectin-4 targeted ADC '701, with potential for a differentated safety... More
